Jacob Blake, MD
Pain Medicine · Reno, NVNPI 1154486769
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,693 of the $7,522 with a category attached, or 75.7%. 23 manufacturers reported payments, led by Boston Scientific at 46.3% of the total.
Across 251 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Relievant Medsystems, Inc.$1K
- Vertiflex, Inc.$1K
- Saluda Medical Americas, Inc.$484
- Medtronic$259
- Stimwave Technologies Incorporated$215
- plus $942 from 17 others
What the payments were for
- Travel & lodging$1,82924%
- Food & beverage$5,69376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 172 | $3,481 |
| Relievant Medsystems, Inc. | 7 | $1,139 |
| Vertiflex, Inc. | 2 | $1,004 |
| Saluda Medical Americas, Inc. | 17 | $484 |
| Medtronic(2 entities) | 6 | $259 |
| Stimwave Technologies Incorporated | 5 | $215 |
| AbbVie(2 entities) | 10 | $185 |
| Nevro Corp. | 7 | $174 |
| SPR Therapeutics, Inc | 6 | $125 |
| Vertos Medical, Inc. | 2 | $112 |
| Abbott | 5 | $102 |
| Globus Medical | 1 | $32 |
| Pfizer | 1 | $30 |
| Vertex | 1 | $25 |
| Avanos Medical | 1 | $23 |
| Assertio Therapeutics, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| MDD US Operations, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,522 in reported general payments places this provider in the 75th percentile of 101 pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GraliseGabapentin | 11 | $8,009 |
| Buprenorphine | 11 | $2,003 |
| Fentanyl | 19 | $1,978 |
| Celecoxib | 18 | $1,385 |
| Buprenorphine Hcl | 21 | $1,345 |
| Gabapentin | 71 | $1,121 |
| Pregabalin | 19 | $585 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $507 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $442 |
| Cyclobenzaprine Hcl | 27 | $398 |
| Duloxetine Hcl | 27 | $256 |
| Hydromorphone Hcl | 12 | $138 |
| Tramadol Hcl | 15 | $45 |
| Meloxicam | 17 | $37 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Reno
- Denis PattersonReno$816K
- Anwar MackReno$32K
- Jonathan BurnsReno$20K
- Ross JensonReno$19K
- Michael GyorfiReno$17K
- Jeffery MuirReno$6K
- Seneca StormReno$2K
- Rainer VogelHenderson$230K
- John DimuroPahrump$44K
- Kunal ParikhLas Vegas$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.